Cargando…
Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy
Over-expression of B7-H1 (PD-L1) molecule in the tumor microenvironment (TME) is a major immune evasion mechanism in some cancer patients and antibody blockade of the B7-H1/PD-1 interaction can normalize compromised immunity without excessive side-effects. Using a genome-scale T-cell activity array,...
Autores principales: | Wang, Jun, Sun, Jingwei, Liu, Linda N., Flies, Dallas B., Nie, Xinxin, Toki, Maria, Zhang, Jianping, Song, Chang, Zarr, Melissa, Zhou, Xu, Han, Xue, Archer, Kristina A., O’Neill, Thomas, Herbst, Roy S., Boto, Agedi N., Sanmamed, Miguel F., Langermann, Solomon, Rimm, David L., Chen, Lieping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7175920/ https://www.ncbi.nlm.nih.gov/pubmed/30833750 http://dx.doi.org/10.1038/s41591-019-0374-x |
Ejemplares similares
-
Development of an Immunohistochemical Assay for Siglec-15
por: Shafi, Saba, et al.
Publicado: (2022) -
Regulation of tumor immunity and immunotherapy by the tumor collagen extracellular matrix
por: Flies, Dallas B., et al.
Publicado: (2023) -
An antibody against Siglec-15 promotes bone formation and fracture healing by increasing TRAP(+) mononuclear cells and PDGF-BB secretion
por: Zhen, Gehua, et al.
Publicado: (2021) -
Blockade of the B7-H1/PD-1 Pathway for Cancer Immunotherapy
por: Flies, Dallas B., et al.
Publicado: (2011) -
Clinical significance of PD-L1 protein expression on tumor-associated macrophages in lung cancer
por: Schalper, Kurt Alex, et al.
Publicado: (2015)